<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="In this review, we summarize the drugs used for COVID-19" exact="treatment" post="in China based on the emerging basic and clinical"/>
 <result pre="prevention, treatment, and control of COVID-19. Keywords COVID-19 SARS-CoV-2 Medical" exact="treatment" post="New drug research and development Introduction An outbreak of"/>
 <result pre="from human to human comparatively, which makes humans vulnerable to" exact="infection" post="and makes it harder to get this outbreak under"/>
 <result pre="In this review, we summarized the drugs used for COVID-19" exact="treatment" post="in China based on the emerging basic and clinical"/>
 <result pre="and indoor herbal medicine fumigation were recommended for prevention and" exact="treatment" post="and have shown pretty good effects [32, 33]. Under"/>
 <result pre="effects [32, 33]. Under the guidance of clinical experience, the" exact="treatment" post="for COVID-19 was divided into medical observation period and"/>
 <result pre="for COVID-19 was divided into medical observation period and clinical" exact="treatment" post="period (confirmed cases). The clinical treatment period (confirmed cases)"/>
 <result pre="observation period and clinical treatment period (confirmed cases). The clinical" exact="treatment" post="period (confirmed cases) is further stratified into four manifestations"/>
 <result pre="of 23 different Chinese medicines are recommended nationwide for the" exact="treatment" post="of mild, severe, and critical symptoms [35]. According to"/>
 <result pre="forms, which could be directly used for the prevention and" exact="treatment" post="of diseases [36â€&quot;42]. Those Chinese medicine formulation used on"/>
 <result pre="or yellow tongue coating, floating pulse Xiyanping injection Chuan-xin-lian Clinical" exact="treatment" post="periodâ€&quot;severe Severe fever and polydipsia, dyspnea and anhelation, delirium,"/>
 <result pre="rapid pulse Xuebijing injection Hong-hua, chi-shao, chuan-xiong, dan-shen, dang-gui Clinical" exact="treatment" post="periodâ€&quot;severe and critical Severe fever and polydipsia, dyspnea and"/>
 <result pre="large and rapid pulse. Reduning injection Qing-hao, jin-yin-hua, zhi-zi Clinical" exact="treatment" post="periodâ€&quot;severe and critical Severe fever and polydipsia, dyspnea and"/>
 <result pre="or large and rapid pulse Shenfu injection Hong-shen, fu-zi Clinical" exact="treatment" post="periodâ€&quot;critical Dyspnea, asthma requires assisted ventilation, dizziness, irritability, cold"/>
 <result pre="floating, and rootless pulse. Shengmai injection Hong-shen, mai-dong, wu-wei-zi Clinical" exact="treatment" post="periodâ€&quot;critical Dyspnea, asthma requires assisted ventilation, dizziness, irritability, cold"/>
 <result pre="she-xiang, zhen-zhu, zhu-sha, xiong-huang, huang-lian, huang-qin, zhi-zi, yu-jin, bing-pian Clinical" exact="treatment" post="periodâ€&quot;clinical period 2 Clearing away heat, detoxifying, calming and"/>
 <result pre="Xiangshaliujun-wan Ban-xia, chen-pi, mu-xiang, sha-ren, dang-shen, bai-zhu, fu-ling, jiu-gan-cao Clinical" exact="treatment" post="periodâ€&quot;clinical period 3 Invigorate the spleen and stomach. Used"/>
 <result pre="moss white greasy Tanreqing injection Huang-qin, xiong-dan, shan-yang-jiao,-jin-yin-hua, lian-qiao Clinical" exact="treatment" post="periodâ€&quot;severe and critical Severe fever and polydipsia, dyspnea and"/>
 <result pre="and rapid pulse Xingnaojing injection She-xiang, bing-pian, zhi-zi, yu-jin Clinical" exact="treatment" post="periodâ€&quot;severe and critical Severe fever and polydipsia, dyspnea and"/>
 <result pre="forms of HIV particles and prevent a new round of" exact="infection" post="[47]. Currently, in vitro studies have shown that lopinavir/ritonavir"/>
 <result pre="Based on that, lopinavir/ritonavir has been recommended for the clinical" exact="treatment" post="of COVID-19 in China. According to the advantages of"/>
 <result pre="that lopinavir/ritonavir should use in the early period of antiviral" exact="treatment" post="to improve clinical symptoms and reduce viral load. The"/>
 <result pre="recommended once a day (800Â mg/200Â mg) that may increase" exact="treatment" post="compliance, reduce adverse reactions, control the spread through urine"/>
 <result pre="[32, 49]. However, the latest research has reported that lopinavir/ritonavir" exact="treatment" post="did not significantly accelerate clinical improvement, reduce mortality, or"/>
 <result pre="both DNA and RNA viruses and widely used for the" exact="treatment" post="of SARS and MERS [43, 51â€&quot;53]. It was recommended"/>
 <result pre="of ribavirin in vitro showed that ribavirin could reduce viral" exact="infection" post="[55]. However, the effectiveness and safety of ribavirin for"/>
 <result pre="prestige medical journal â€œNew England Medical Journalâ€� (NEJM) reported the" exact="diagnosis" post="and treatment process of the first SARS-CoV-2 infected patient"/>
 <result pre="journal â€œNew England Medical Journalâ€� (NEJM) reported the diagnosis and" exact="treatment" post="process of the first SARS-CoV-2 infected patient in the"/>
 <result pre="USA, showing that remdesivir has a certain role in the" exact="treatment" post="[25, 54, 66]. Cell research published an article stating"/>
 <result pre="marketed in China, and the indication was approved for the" exact="treatment" post="of new or recurrent epidemics in adults. Thus, favipiravir"/>
 <result pre="epidemics in adults. Thus, favipiravir became a potential drug for" exact="treatment" post="of COVID-19 patients [73]. In a small-scale clinical trial"/>
 <result pre="a nucleoside reverse transcriptase inhibitor which is used in AIDS" exact="treatment" post="[78, 79]. It blocks the reverse transcription process of"/>
 <result pre="of emtricitabine and denofovir alafenamide in clinical trial for the" exact="treatment" post="of COVID-19 was applied with great therapeutic effects [32]."/>
 <result pre="[32]. Chloroquine Phosphate Chloroquine phosphate is mainly used in the" exact="treatment" post="of malaria and rheumatism in clinical [81â€&quot;83]. Numerous studies"/>
 <result pre="has been found that chloroquine phosphate could effectively inhibit the" exact="infection" post="of coronavirus at the cellular level [85â€&quot;87]. It has"/>
 <result pre="the cellular level [85â€&quot;87]. It has been recommended for antiviral" exact="treatment" post="of the COVID-19 as well [88]. Hydroxychloroquine Hydroxychloroquine was"/>
 <result pre="as an antimalarial drug and has been used for the" exact="treatment" post="of rheumatoid arthritis and lupus erythematosus [89â€&quot;91]. Due to"/>
 <result pre="has been reported that some COVID-19 patients benefited from the" exact="treatment" post="with hydroxychloroquine [96â€&quot;99]. Moreover, its effect for virus elimination"/>
 <result pre="very important immune protective cytokine in human response to virus" exact="infection" post="[100, 101]. It could induce the same cell to"/>
 <result pre="Moreover, IFN-Î± has been recommended to be applied in the" exact="treatment" post="of COVID-19 recently [32]. Tocilizumab Injection Tocilizumab injection is"/>
 <result pre="critical diseases [108]. Tocilizumab injection has been recommended as a" exact="treatment" post="for COVID-19 by researchers at University of Science and"/>
 <result pre="and immunosuppressive agent in clinical practice [110, 111]. During the" exact="treatment" post="of COVID-19, it is recommended to be used for"/>
 <result pre="WHO recommends that glucocorticoids are not suitable for the routine" exact="treatment" post="of COVID-19 except in clinical trials [11, 113, 114]."/>
 <result pre="recovery plasma therapy is still an exploratory treatment. The current" exact="diagnosis" post="and treatment scheme is recommended to try in severe"/>
 <result pre="therapy is still an exploratory treatment. The current diagnosis and" exact="treatment" post="scheme is recommended to try in severe patients and"/>
 <result pre="regulator could maintain intestinal microecological balance and prevent secondary bacterial" exact="infection" post="[32]. Perspective As for a new emerging acute infectious"/>
 <result pre="no specific antiviral drugs. All options for its prevention and" exact="treatment" post="are based on previous experience in the treatment of"/>
 <result pre="prevention and treatment are based on previous experience in the" exact="treatment" post="of SARS, MERS, or other new influenza viruses. Active"/>
 <result pre="treatment of SARS, MERS, or other new influenza viruses. Active" exact="treatment" post="based on the patientâ€™s symptoms is still the main"/>
 <result pre="optimistic. The Chinese Health Commission has established several versions of" exact="diagnosis" post="and treatment plans on COVID-19, which was formulated in"/>
 <result pre="Chinese Health Commission has established several versions of diagnosis and" exact="treatment" post="plans on COVID-19, which was formulated in a short"/>
 <result pre="at present. Since these drugs were not developed for the" exact="treatment" post="of COVID-19, the clinical therapeutic effect is surely limited."/>
 <result pre="involved medicines still need to be confirmed in further clinical" exact="treatment" post="and research. Even though those medicines we used have"/>
 <result pre="and development of specific medicine and vaccine according to the" exact="infection" post="mechanism and characteristic structure of new crown virus. What"/>
 <result pre="after the epidemic is a bit more in doubt. The" exact="isolation" post="and structure analysis of various coronaviruses have been completed"/>
 <result pre="developed a corresponding durable immunity. However, compared with the transient" exact="infection" post="of virus epidemic, the new drug development cycle is"/>
 <result pre="possible future coronavirus epidemic. Conclusions The drugs used for COVID-19" exact="treatment" post="in China based on the emerging basic and clinical"/>
 <result pre="24.CunninghamACGohHPKohDTreatment of COVID-19: old tricks for new challengesCrit Care20202419132178711 25.LuHDrug" exact="treatment" post="options for the 2019-new coronavirus (2019-nCoV)Biosci Trends2020141697131996494 26.Raoult D;"/>
 <result pre="Cui L; Yu J; Cao H; Li L, Early antiviral" exact="treatment" post="contributes to alleviate the severity and improve the prognosis"/>
 <result pre="treatmentPharmacol Res202015510474332145402 31.Guidance for corona virus disease 2019: prevention, control," exact="diagnosis" post="and management. 2020, (People's Medical Publishing House), 146. 32.Chan"/>
 <result pre="L; Yang H; Huang G; Yang R, Clinical features and" exact="treatment" post="of COVID-19 patients in Northeast Chongqing. J Med Virol"/>
 <result pre="2020, 104761. 37.HeJLiZHuangWGuanWMaHYangZFWangXEfficacy and safety of Chou-Ling-Dan granules in the" exact="treatment" post="of seasonal influenza via combining Western and traditional Chinese"/>
 <result pre="Decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1) virus" exact="infection" post="in vitro and in vivo. Viruses 2018, 10, (3)."/>
 <result pre="herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus" exact="infection" post="through activation of heme oxygenase-1Acta Pharm Sin B20177663063729159022 40.ZouWWangJLiuYEffect"/>
 <result pre="Digestive and Kidney Diseases: Bethesda (MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments in early" exact="diagnosis" post="and therapy of HIV infection in newbornsExpert Opin Pharmacother2018191132528764578"/>
 <result pre="(MD), 2012. 45.CanalsFMasiÃ¡MGutiÃ©rrezFDevelopments in early diagnosis and therapy of HIV" exact="infection" post="in newbornsExpert Opin Pharmacother2018191132528764578 46.Coelho AV; Tricarico PM; Celsi"/>
 <result pre="Pharmacother2018191132528764578 46.Coelho AV; Tricarico PM; Celsi F; Crovella S, Antiretroviral" exact="treatment" post="in HIV-1-positive mothers: neurological implications in virus-free children. Int"/>
 <result pre="the IMPAACT P1060 randomized trialClin Infect Dis20166381113112127439527 48.MoYFisherDA review of" exact="treatment" post="modalities for Middle East respiratory syndromeJ Antimicrob Chemother201671123340335027585965 49.Martinez"/>
 <result pre="severe Covid-19. N Engl J Med 2020. 51.JordanPCStevensSKDevalJNucleosides for the" exact="treatment" post="of respiratory RNA virus infectionsAntivir Chem Chemother201826204020661876448329562753 52.RabaanAAAlahmedSHBazziAMAlhaniHMA review"/>
 <result pre="2012 to 2016 in FranceJ Antimicrob Chemother201974113305331431384941 75.SpagnuoloVCastagnaALazzarinADarunavir for the" exact="treatment" post="of HIV infectionExpert Opin Pharmacother201819101149116329913082 76.Llibre, J. M., Development"/>
 <result pre="of a three day course of tafenoquine monotherapy for the" exact="treatment" post="of Plasmodium vivax malariaPLoS One20171211e018737629121061 83.BaruahUKGowthamarajanKRavisankarVKarriVSimhadriPKSinghVOptimisation of chloroquine phosphate"/>
 <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin"/>
 <result pre="Dis 2020. 86.GaoJTianZYangXBreakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studiesBiosci Trends2020141727332074550 87.Expert"/>
 <result pre="clinical studiesBiosci Trends2020141727332074550 87.Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia. Zhonghua Jie He He Hu"/>
 <result pre="JM; Brouqui P; Raoult D, Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061632194981 99.Sahraei Z; Shabani M; Shokouhi S;"/>
 <result pre="Antimicrob Agents 2020, 105945. 100.SnellLMMcGahaTLBrooksDGType I interferon in chronic virus" exact="infection" post="and cancerTrends Immunol201738854255728579323 101.Sen N; Sung P; Panda A;"/>
 <result pre="Virol 2018, 92, (21). 102.LiHSKuokDITCheungMCNgMMTNgKCHuiKPYPeirisJSMChanMCWNichollsJMEffect of interferon alpha and cyclosporine" exact="treatment" post="separately and in combination on Middle East respiratory syndrome"/>
 <result pre="and Î²) against Zika virusJ Med Virol201890181228851097 104.SanmartÃ­RRuiz-EsquideVBastidaCSoyDTocilizumab in the" exact="treatment" post="of adult rheumatoid arthritisImmunotherapy201810644746429495891 105.AhnSSJungSMSongJJParkYBParkJYLeeSWSafety of tocilizumab in rheumatoid"/>
</results>
